Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients

Telman, Gregory; Kouperberg, Efim; Sprecher, Elliot; Yarnitsky, David

doi:10.1016/j.jns.2009.03.024

Cited by 6 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed that prestroke use of AP independently increased odds for being alive and independent at discharge, which is consistent with some but not all previous studies. Noteworthy, the one neutral study did not include patients older than 65 years. In our cohort median age ranged from 62 to 83, which may partly explain the difference.…”

Section: Discussionsupporting

confidence: 93%

Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Six studies specifically examined the effect of aspirin monotherapy on stroke aetiology ( n = 3744) . The remainder of studies included in the statistical analyses examined cohorts with mixed prescription of various antiplatelet agents or dual antiplatelet therapy ( n = 1995).…”

Section: Resultsmentioning

confidence: 99%

“…Eight full text articles were eligible for inclusion and contained data suitable for statistical analysis [12][13][14][15][16][17][18][19]. One article contained data for two separate studies [12].…”

Section: Resultsmentioning

confidence: 99%

“…For this reason, one could hypothesize that the primary prevention subgroup should give a more accurate estimate of the true effect size. However, our subgroup analysis of primary prevention contained data from only three small trials [13,16,19]. Although concordant non-significant trends were observed using both fixed and random effects models, there was significant heterogeneity and the analyses were underpowered for discrimination of the true effect.…”

Section: Primary Preventionmentioning

confidence: 89%

“…A number of studies have examined this relationship. However there is disagreement in the published literature and the true magnitude of any effect is unclear [12][13][14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Antiplatelet therapy as a modulator of stroke aetiology: a meta‐analysis

Rajkumar

Floyd

Ferro

2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

* These authors contributed equally. AIMSAntiplatelet therapy reduces the incidence of ischaemic stroke. Plateletmediated thrombosis contributes variably to the major subtypes of stroke as defined by the TOAST criteria: large artery atherosclerosis (LAA), cardioembolic (CE) and small vessel occlusion (SVO). The effect of antiplatelet therapy on the incidence of each subtype is unknown and is the subject of this meta-analysis. METHODSElectronic databases were searched for articles comparing the effect of antiplatelet therapy on the incidence of stroke according to aetiological subtype. Studies containing subjects prescribed anticoagulant therapy or solely investigating subjects with atrial fibrillation were excluded. Pooled odds ratios (ORs) were calculated using a fixed effects model. RESULTSNine studies were included (n = 5739). In patients who had an ischaemic stroke, pre-event antiplatelet therapy was associated with significantly decreased incidence of LAA (OR 0.88, 95% CI 0.79, 0.99; P = 0.026), increased incidence of CE (OR 1.23, 95% CI 1.08, 1.41; P = 0.002) and no effect on SVO (OR 0.99, 95% CI 0.88, 1.11; P = 0.806). Concordant nonsignificant trends were observed in primary prevention populations (n = 751): LAA (OR 0.81, 95% CI 0.57, 1.15; P = 0.240), CE (OR 1.29, 95% CI 0.89, 1.87; P = 0.179) and SVO (OR 0.99, 95% CI 0.73, 1.36; P = 0.970). Subgroup analysis of aspirin monotherapy (n = 3786) demonstrated a significant reduction in LAA (OR 0.87, 95% CI 0.76, 1.00; P = 0.046), but non-significant effects on the incidence of CE (OR 1.17, 95% CI 0.99, 1.39; P = 0.068) and SVO (OR 1.04, 95% CI 0.91, 1.20; P = 0.570). Probability of publication bias was low (P > 0.05). CONCLUSIONSAntiplatelet therapy preferentially reduces the incidence of LAA stroke compared with CE and SVO subtypes.--

show abstract

Clinical Applications of Aspirin

Schrör

2008

Acetylsalicylic Acid

View full text Add to dashboard Cite

Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients

Cited by 6 publications

References 25 publications

Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome

Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome

Antiplatelet therapy as a modulator of stroke aetiology: a meta‐analysis

Clinical Applications of Aspirin

Contact Info

Product

Resources

About